BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, December 30, 2024
Breaking News: Holiday special – 25% off BioWorld subscriptions
See today's BioWorld Science
Home
» JAK1/JAK2/TYK2 inhibitors reported in Hangzhou Highlightll Pharmaceutical patent
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Dermatologic
JAK1/JAK2/TYK2 inhibitors reported in Hangzhou Highlightll Pharmaceutical patent
March 18, 2024
No Comments
Work at Hangzhou Highlightll Pharmaceutical Co. Ltd. has led to the development of tyrosine-protein kinase JAK1, JAK2 and non-receptor tyrosine-protein kinase TYK2 inhibitors.
BioWorld Science
Dermatologic
Patents
